Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-42160443 · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | JNJ-42160443 Type=1 unit=mg number=10 form=solution for injection route=subcutaneous use. SC injection (10mg/ml) once every 4 weeks for up to 52 weeks |
| 002 | PLACEBO_COMPARATOR | Placebo Form=solution for injection route=subcutaneous use. SC injection (0.9 mL matching placebo) once on Day 1 |
| Name | Type | Description |
|---|---|---|
| JNJ-42160443 | DRUG | Type=1, unit=mg, number=10, form=solution for injection , route=subcutaneous use. SC injection (10mg/ml) once every 4 weeks for up to 52 weeks |
| Placebo | DRUG | Form=solution for injection, route=subcutaneous use. SC injection (0.9 mL matching placebo) once on Day 1 |
Inclusion Criteria: * Terminally ill cancer patients as per judgment of the investigator (eg, patients who are in or who are candidates for hospice or palliative care for end-of-life management); Diagnosis of moderate to severe pain directly related to an active cancer that is not controlled by sta...
JNJ-42160443 is an investigational small molecule being studied for the treatment of pain, including burning, crushing, migratory, radiating, and splitting pain. It is being evaluated as an add-on treatment in patients with cancer-related pain. The drug is currently in Phase 2 clinical development.
JNJ-42160443 is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker symbol JNJ. The drug is an investigational small molecule in Phase 2 clinical development for the treatment of pain.
JNJ-42160443 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 clinical trial studying the drug as an add-on treatment for cancer-related pain has been completed.
JNJ-42160443 has one completed Phase 2 clinical trial, identified as NCT00929188. This study evaluated the safety and effectiveness of JNJ-42160443 as an add-on treatment in patients with cancer-related pain. The trial enrolled 100 participants and was conducted in the United States, France, Poland, Portugal, and Spain.
JNJ-42160443 is the drug name used in clinical trials. No alternative names have been reported for this investigational compound. It is being developed by Johnson & Johnson for the treatment of pain.